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The toxic equivalency concept used for the risk assessment
of polychlorinated biphenyls (PCBs) is based on the aryl hydrocarbon
receptor (AhR)–mediated toxicity of coplanar dioxin-like (DL) PCBs.
Most PCBs in the environment, however, are non-dioxin-like (NDL)
PCBs that cannot adopt a coplanar structure required for AhR
activation. For NDL-PCBs, no generally accepted risk concept is
available because their toxicity is insufficiently characterized. Here, we
systematically determined in vitro toxicity profiles for 24 PCBs
regarding 10 different mechanisms of action. Prior to testing, NDL-
PCB standards were purified to remove traces of DL compounds. All
NDL-PCBs antagonized androgen receptor activation and inhibited
gap junctional intercellular communication (GJIC). Lower chlori-
nated NDL-PCBs were weak estrogen receptor (ER) agonists, whereas
higher chlorinated NDL-PCBs were weak ER antagonists. Several
NDL-PCBs inhibited estradiol-sulfotransferase activity and
bound to transthyretin (TTR) but with much weaker potencies
than reported for hydroxylated PCB metabolites. AhR-mediated
expression of uridine-glucuronyl transferase isozyme UGT1A6
was induced by DL-PCBs only. Hierarchical cluster analysis of the
toxicity profiles yielded three separate clusters of NDL-PCBs and
a fourth cluster of reference DL-PCBs. Due to small differences in
relative potency among congeners, the highly abundant indicator
PCBs 28, 52, 101, 118, 138, 153, and 180 also contributed most
to the antiandrogenic, (anti)estrogenic, antithyroidal, tumor-
promoting, and neurotoxic potencies calculated for PCB mixtures
reported in human samples, whereas the most potent AhR-
activating DL-PCB-126 contributed at maximum 0.2% to any of
these calculated potencies. PCB-168 is recommended as an
additional indicator congener, given its relatively high abundance
and antiandrogenic, TTR-binding, and GJIC-inhibiting potencies.
Key Words: polychlorinated biphenyls; endocrine disruption;
thyroid hormone; steroid hormone; cell communication; neurotoxicity.
Polychlorinated biphenyls (PCBs) are synthetic organic
compounds, with high resistance against electrical, thermal,
chemical, or biological breakdown. Despite the ban on their
production, PCBs remain to be an environmental problem due
to their high persistency and ongoing ‘‘leaking’’ to the environ-
ment from existing applications and waste.
Based on their toxicological mechanism of action, PCB
congeners can be divided into two groups. The first group
consists of PCB congeners, which can adopt a coplanar structure,
because they have zero or one chlorine substitution in the ortho
position. Similar to polychlorinated dibenzo-p-dioxins and
dibenzofurans (PCDD/Fs), these coplanar PCBs can bind to
the aryl hydrocarbon receptor (AhR) transcription factor and
exert dioxin-like (DL) toxicity via AhR activation. For PCDD/Fs
and DL-PCBs, the World Health Organization derived toxicity
equivalency factors (TEF values), expressing their relative AhR-
mediated toxicity compared with 2,3,7,8-tetrachloro-dibenzo-
p-dioxin (Van den Berg et al., 2006). A toxic equivalency (TEQ)
concentration of a DL compound is determined by multiplying
its concentration with its compound-specific TEF value. TEQ
concentrations of individual DL compounds can be summarized
according to the principle of concentration addition, and risk
assessment of a mixture of DL compounds in humans is
performed by comparing the total TEQ intake to a tolerable
weekly intake of 14 pg TEQ/kg body weight (SCF, 2000, 2001).
In contrast to DL-PCBs, the toxicity profiles of non–dioxin-
like (NDL-PCBs) are insufficiently characterized. Consequently,
no risk assessment model similar to the TEQ concept is available
for NDL-PCBs, although various adverse effects on thyroid,
liver, brain, immune system, estrous cycling, reproduction, and
neurodevelopment have been reported for animal studies with
individual NDL-PCB congeners (EFSA, 2005). The risk
characterization of NDL-PCBs is hampered by the fact that
only a minor contamination of the NDL-PCBs with DL com-
pounds such as DL-PCBs and PCDD/Fs is sufficient to explain
the observed effects, given the much higher toxicity of DL
compounds to affect certain endpoints. Because most studies
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used non-purified NDL-PCB standards, contaminations with
DL-PCBs and PCDD/Fs are realistic and it cannot be concluded
whether the observed effects are true NDL-PCB effects or
caused by DL contaminations.
In order to improve the hazard characterization of NDL-
PCBs, the aims of the present systematic in vitro screening study
were (1) to screen the toxic potency of structurally representative
and highly purified NDL-PCBs to identify relevant mechanisms
of action for NDL-PCBs in man and wildlife, (2) to classify
NDL-PCBs into clusters with similar toxicity profiles, and (3) to
determine the relative importance of individual NDL-PCB
congeners to the calculated toxic potency of a complex mixture
of PCBs present in human samples (blood and adipose tissue).
Most PCB research has focused on a set of seven indicator
PCB congeners representing the most abundant and well-
studied PCBs in the environment, i.e., PCBs 28, 52, 101, 118,
138, 153, and 180. PCB-118 is the only DL-PCB in this set for
which a TEF value has been derived, whereas the other 6
NDL-PCB congeners are considered to represent about 50%
of the total PCB level in food (EFSA, 2005). The test set of
PCBs in the present study consisted of the seven indicator
PCBs extended with another set of 13 mono- to tetra-ortho-
chlorinated PCBs 19, 47, 51, 53, 74, 95, 100, 104, 122, 128,
136, 170, and 190 previously selected by Stenberg and
Andersson (2008) to span the structural and chemical variation
domain of NDL-PCBs. This set was further extended with
PCB-80 (a positive control for the transthyretin [TTR]-binding
assay; Chauhan et al., 2000) and PCBs 125 and 168, rep-
resenting PCB congeners with two chlorine substitutions in
ortho position on one phenyl ring and none on the other.
Finally, the non–ortho-substituted PCB-126 was added to the
set as a reference structure for DL-PCBs. The complete test set
of PCBs including their substitution pattern, molecular weight,
and structural formula is given in Supplementary figure 1.
All 24 PCBs were tested for their potencies to interact with
the estrogen receptor (ER) and the androgen receptor (AR), to
inhibit sulfonation of estradiol (E2) by estradiol-sulfotransferase
(E2SULT), to compete with thyroid hormone thyroxine (T4) for
binding to its plasma transport protein TTR, to alter expression
of uridine-glucuronyl transferase isozymes (UGT1A1 and
UGT1A6) and deiodinase-1 (DI-1) involved in thyroid hormone
metabolism, and to inhibit gap junctional intercellular commu-
nication (GJIC), a parameter related closely to tumor promotion.
Altogether, all compounds were tested in eight different
bioassays for 10 different mechanisms of action (Table 1).
For each mechanism of action, relative potency (REP)
factors were calculated for each individual PCB congener as
the ratio between the EC50 values of a positive reference
compound (Table 1) and the PCB congener of interest. Classes
of PCBs with similar toxicity profiles were determined using
hierarchical cluster analysis (HCA) and evaluated for possible
common structural characteristics. Finally, the relative contri-
bution was estimated of different PCB congeners, or their
classes, to the overall toxic potency of complex PCB mixtures
determined in human samples. To this end, PCB concentrations
determined in blood and adipose tissue from normal human
populations were converted into equivalent concentrations of
specific reference compounds for each specific mechanism of
action studied using the REP factors determined for the
individual PCB congeners.
MATERIALS AND METHODS
Chemicals. All 24 PCB standards (Supplementary fig. 1) were purchased
from Neosyn Inc. Each PCB was dissolved in n-hexane and purified on
a charcoal carbon column mixed with celite, as described in detail by Danielsson
et al. (2008). Purification efficiency was assessed by applying the cleaned
standard on a second carbon/celite column eluting the PCB using n-hexane
followed by backflushing the column with toluene for analysis of DL-PCBs and
PCDD/Fs. These tests indicated only trace levels (< pg/g) of DL compounds in
the purified NDL-PCB standards. Ultimately, 25mM stock solutions and further
dilution series of the PCB standards were prepared in dimethylsulfoxide
(DMSO). Using a similar approach as described for the PCB standards, only
trace levels (< pg/g) of DL impurities were identified in the DMSO batch used in
all experiments.
TABLE 1
Overview of the Eight In Vitro Bioassays Used to Determine the Toxic Potency of NDL-PCBs for 10 Different
Mechanisms of Action Ordered per Type of Activity
Activity Bioassay Reference material Mechanism of action
Maximum PCB test
concentration (lM)
Estrogenic ER-CALUX 17b-estradiol (E2) ER activation 25
E2SULT Pentachlorophenol (PCP) Inhibited sulfonation (metabolism) of E2
Antiestrogenic ER-CALUX ICI-182,780 Competing with E2 for ER 25
Androgenic AR-CALUX DHT AR activation 10
Antiandrogenic AR-CALUX Flutamide (Flu) Competing with DHT for AR 10
Antithyroidal TTR binding T4 Displacing T4 from TTR 10
UGT1A1 expression Hexabromocyclododecane Induced glucuronidation of T4 10
UGT1A6 expression Aroclor 1254 Induced glucuronidation of T4 10
deiodinase-1 expression 3,3#,5-triiodothyronine (T3) Induced deiodinization of T4 10
Tumor promoting GJIC inhibition PCB-136 Decreased communication between
neighboring cells
50
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Bioassay data analysis. A complete list of bioassays together with its
mechanism of action, reference compound, and maximum test concentration is
provided in Table 1. For a detailed description of experimental procedures, see
Supplementary data. Dose-response curves were calculated, and concentrations
corresponding with 50% effect (EC50) or inhibition (IC50) were determined at
half (50%) of the maximum response level induced by the reference
compounds (Table 1). EC50 or IC50 values exceeding the highest test
concentration were set at a minimum value (Table 4).
If possible, in vitro toxic potencies of the PCBs were classified based
on EC50 or IC50 values according to the criteria previously used by Hamers
et al. (2006):
(1) No potency: Response < 20% at 10lM
(2) Weak potency: (EC50 or IC50) > 10lM and response > 20% at 10lM
(3) Moderate potency: 1lM < (EC50 or IC50)  10lM
(4) High potency: 0.1lM < (EC50 or IC50)  1lM
(5) Very high potency: 0.01lM < (EC50 or IC50)  0.1lM
Although no exact IC50 values could be calculated for the E2SULT
inhibition assay (see Results section), its results could still be classified
according to these criteria because the order of magnitude of IC50 values could
be assessed from the observed dose-response relationships. Finally, gene
expression results were only determined at 10lM exposure concentrations.
By setting the highest UGT1A6 induction by PCB-126 to 100%, it could be
deduced that the 50% induction level was reached by the other PCB congeners
in the range 1–10lM (class 3).
Toxicity profiles based on classified bioassay responses were analyzed with
HCA in SPSS (version 16.0 for Windows) using the between-group linkage
method based on squared Euclidean distances between class values, similar as
described for polybrominated diphenyl ethers (PBDEs) by Hamers et al.
(2006). In HCA, PCBs were clustered together according to similarity in
toxicity profile, and the results are presented as a dendrogram, i.e., a diagram
illustrating which PCBs cluster together at successive stages of HCA and
indicating the relative distance in toxicity profile between the individual PCB
congeners and between the distinguished clusters of PCBs.
Toxic potency of complex PCB mixtures in human samples. To
determine total toxic potencies of PCBs in human samples for each endpoint,
3 studies were selected, in which ‘‘average’’ human levels were reported for as
many of the tested 24 congeners as possible, including the most potent AhR-
activating PCB-126 (reference DL-PCB). Wingfors et al. (2000) reported PCB
levels in blood and adipose tissue for two general populations in Spain and in
Sweden. Hirai et al. (2005) analyzed PCBs in whole blood samples from
healthy adult Japanese volunteers, and Wang et al. (2010b) in adipose tissue
from a rural and an urban population in Southeast China. Out of the 24
congeners for which REP factors are reported in the present study, levels of 13
(54%; Spain and Sweden) to 15 (63%; Japan and China) PCB congeners were
available. Mean PCB concentrations and number of samples analyzed reported
in the three selected studies are presented in Supplementary table 1. For each
mechanism of action, the total toxic potencies were calculated as a sum of the
mean levels of each congener in humans multiplied by its respective REP factor
for that mechanism of action determined in the present study (see Supplementary
data for more details). Similarly, neurotoxic potencies of the PCB levels in
human samples were calculated using neurotoxic REP values (Supplementary
table 2) determined by Simon et al. (2007).
RESULTS
Bioassay Results
All tested PCBs showed antiandrogenic effects in the AR-
CALUX bioassay (Table 2), and none of them had androgenic
effects. The highest AR-antagonistic potencies (IC50 between
0.1 and 1lM) were found for PCB congeners 168, 125, 19,
122, 104, 128, 51, 126, 47, 136, and 28. Most PCBs had higher
AR-antagonistic potency than the reference compound fluta-
mide, an antiandrogenic drug used in prostate cancer treatment,
whereas their potencies were in the same order of magnitude as
those reported for PBDEs PBDE-100 and PBDE-47 (IC50 ¼
0.1 and 1.0lM, respectively), which are the strongest AR
antagonists with environmental relevance reported to date
(Hamers et al., 2006). For most PCB congeners, the AR-
antagonistic potencies could be counteracted by addition of an
excess concentration of 200nM dihydrotestosterone (DHT), but
not for PCBs 118, 122, 180, and 190. Nevertheless, visual
observations and the resazurin viability assay did not indicate
any cytotoxic effects of these PCBs in the U2OS cells of the
AR-CALUX bioassay at 10lM.
Out of the tri- or tetrachlorinated congeners, PCBs 19, 28, 47,
51, and 53 exhibited significant but weak estrogenic activity in
the ER-CALUX bioassay with EC50 values ranging from 5 to
15lM, but PCB-52 and PCB-74 did not (Table 3). Out of
the pentachlorinated congeners, PCB-104 was the most potent
estrogenic congener of the whole test set (EC50¼ 3lM), whereas
PCB-100, and to a lesser extent PCB-95 and PCB-125, also
TABLE 2
AR-Antagonistic Responses of the 24 PCBs and the Positive
Reference Compound Flutamide in the AR-CALUX Assay
Compound
AR antagonistic
IC50 (lM) ± SD
Flutamide-
REP ± SD
Luciferase activity at
10lM PCB (% control)
PCB-19 0.38 ± 0.05 7.8 ± 0.1 19
PCB-28 0.76 ± 0.36 4.6 ± 1.9 1
PCB-47 0.60 ± 0.03 5.6 ± 0.2 1
PCB-51 0.50 ± 0.03 5.8 ± 0.3 8
PCB-52 3.2 ± 1.5 1.1 ± 0.5 29
PCB-53 1.3 ± 0.2 2.4 ± 0.4 19
PCB-74 2.1 ± 0.2 1.6 ± 0.0 11
PCB-80 1.6 ± 0.3 2.0 ± 0.3 29
PCB-95 1.4 ± 0.2 2.1 ± 0.0 8
PCB-100 1.0 ± 0.2 3.3 ± 0.6 7
PCB-101 2.7 ± 0.4 1.1 ± 0.0 21
PCB-104 1.9 ± 0.6 1.7 ± 0.5 9
PCB-118 0.47 ± 0.01 7.0 ± 0.4 1
PCB-122 0.39 ± 0.00 8.6 ± 0.7 0
PCB-125 0.25 ± 0.03 13 ± 2 2
PCB-126 0.53 ± 0.14 5.7 ± 0.8 5
PCB-128 0.48 ± 0.02 6.9 ± 0.2 0
PCB-136 0.71 ± 0.16 4.2 ± 0.5 0
PCB-138 1.0 ± 0.3 3.2 ± 0.9 0
PCB-153 8.5 ± 4.1 0.43 ± 0.23 22
PCB-168 0.16 ± 0.01 20 ± 1 2
PCB-170 1.1 ± 0.1 3.1 ± 0.0 3
PCB-180 2.1 ± 0.3 1.4 ± 0.33 8
PCB-190 1.3 ± 0.2 2.2 ± 0.0 2
Flutamide 3.1 ± 0.3 1.0 ± 0.1 16
Note. AR-antagonistic potencies were tested in the presence of 200pM DHT;
n ¼ 2.
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exhibited ER-mediated activity. PCB-136 was the only hexa-
chlorobiphenyl in the test set eliciting ER-mediated activity
(EC50 ¼ 6lM). Other pentachlorobiphenyls (including mono-
ortho-chlorinated PCB-118 and coplanar PCB-126) and hexa-
chlorobiphenyl PCB-128 elicited no effect in the ER-CALUX
bioassay. All other hexa- and heptachlorinated PCBs studied
(i.e., PCBs 138, 153, 168, 170, 180, and 190) exhibited weak
antiestrogenic activities at micromolar concentrations (IC50
values ranging from 14 to > 25lM).
E2SULT-inhibiting potency was found for many tested PCBs
at concentrations ranging between 1 and 10lM (Table 4).
Highest E2SULT-inhibiting activity was found for PCBs 100,
101, and 138, although no clear dose-response relationship could
be observed for the latter congener. For PCBs 47, 100, 101, and
104, dose-response curve fits were too unreliable to report IC50
values in Table 4, as shown in Figure 1.
TTR-binding capacity was observed for only a few PCBs
(Table 4): full dose-response curves could only be determined
for PCBs 80, 122, 125, and 168. Full inhibition (i.e., 100%
replacement of T4 from TTR) was observed for PCB-125 and
PCB-168, which have high structural similarity to T4, whereas
maximum inhibition by PCB-80 and PCB-122 leveled off to
inhibition levels of 40–55%, respectively. Increasing test
concentrations of these 2 congeners did not lead to further
inhibition. As a result, no IC50 value could be determined for
PCB-80 (Fig. 1). Based on its relatively high TTR-binding
potency at sub-micromolar levels (Fig. 1), however, PCB-80 was
arbitrarily classified in class 3 (moderately high) and not in class
1 for this bioassay. Very weak TTR-binding activities were
found for PCB congeners 138, 153, 170, 180, and 190, showing
> 20% inhibition at the highest test concentration (10lM).
In the rat hepatoma H4IIE cell line, exposure to 10lM of
DL-PCBs 74, 118, or 126 caused an upregulation of UGT1A6
messenger RNA (mRNA) expression up to a factor 2.8. PCB-138
was the only NDL-PCB in the test set causing an upregulation of
UGT1A6 up to a factor 1.5. None of the PCB congeners tested
affected mRNA expression of UGT1A1 or DI-1.
NDL-PCB congeners with 2,2,#6 substitution (PCBs 19,
51, 53, 95, 104, and 136) had moderate GJIC-inhibiting
potencies with IC50 values ranging from 5 to 8lM (Table 5),
except for 2,2,#4,4,#6-substituted PCB-100 (IC50 ¼ 16lM).
Out of the six indicator PCBs, PCB-52 also had a moderate
TABLE 3
ER-Agonistic and Antagonistic Responses of the 24 PCBs and Positive Reference Compounds E2 and ICI-182,780,
Respectively, in the ER-CALUX Assay
Compound
ER agonistic ER antagonistic
EC50 (lM) ± SD E2-REP ± SD
Response at
10lM (% E2 max) IC50 (lM) ± SD
ICI-182,780
REP ± SD
Luciferase activity at
10lM PCB (% control)
PCB-19 12 ± 4 13 3108 55 — — 120
PCB-28 26 ± 2 6.0 3 108 15 — — 100
PCB-47 21 ± 2 7.4 3 108 31 — — 100
PCB-51 12 ± 2 13 3 108 61 — — 101
PCB-52 — — 8 — — 100
PCB-53 25 ± 12 6.1 3 108 18 — — 110
PCB-74 — — 2 — — 100
PCB-80 — — 3 — — 114
PCB-95 — — 10 — — 105
PCB-100 13 ± 1 12 3 108 58 — — 85
PCB-101 — — 0 — — 83
PCB-104 3 ± 1 46 3 108 122 — — 171
PCB-118 — — 0 — — 100
PCB-122 — — 0 — — 90
PCB-125 — — 7 — — 100
PCB-126 — — 0 — — 100
PCB-128 — — 10 — — 93
PCB-136 6 ± 1 25 3 108 80 — — 124
PCB-138 — — 0 16 ± 1 1.8 3 106 65
PCB-153 — — 0 24 ± 3 1.3 3 106 69
PCB-168 — — 2 — — 125
PCB-170 — — 0 24 ± 2 1.3 3 106 80
PCB-180 — — 0 14 ± 5 2.2 3 106 60
PCB-190 — — 0 18 ± 3 1.7 3 106 68
E2 (16 ± 6.1) 3 107 1.0 100 ND ND ND
ICI-182,780 ND ND ND (30 ± 4.9) 3 106 1.0 0
Note. ER-antagonistic potencies were tested in the presence of 6pM E2; n ¼ 3; —, no response; ND; not determined.
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GJIC-inhibiting potency (IC50 ¼ 9lM), whereas the most
abundantly occurring PCBs in the environment, PCB-138 and
PCB-153, along with other di-ortho- and mono-ortho-
substituted PCBs, had weak potencies (IC50 > 10lM). Out of
these weak GJIC-inhibiting congeners, heptachlorinated PCBs
170, 180, and 190 had again weaker GJIC inhibitory potencies
(IC50  23lM) than tri- to hexachlorinated PCBs (IC50 <
23lM). Non–ortho-substituted PCBs 80 and 126 had no effect
on GJIC.
Toxicity Profiling
Based on their toxicity profiles, the test set of PCBs could be
divided in four different clusters by multivariate HCA (Fig. 2).
Cluster I consisted of NDL-PCBs with moderate to high
AR-antagonistic potencies and weak TTR-binding, GJIC-inhibit-
ing, and antiestrogenic potencies. This cluster contained the most
abundant environmental PCB congeners: 138, 153, 170, and 180.
Cluster II had moderate to high AR-antagonistic and TTR-
binding potencies and weak GJIC-inhibiting potencies. Cluster
III consisted of DL-PCBs with moderate UGT1A6-inducing
potencies via AhR activation and moderate to high AR-
antagonistic potencies. Cluster IV consisted of NDL-PCBs with
moderate to high AR-antagonistic potencies, weak to moderate
GJIC-inhibiting and E2SULT-inhibiting potencies, and no TTR-
binding potencies. Two subclusters could be further distin-
guished, based on the absence (IV.1) or presence (IV.2) of weak
ER-agonistic potencies. The tetra-ortho-substituted PCBs 104
TABLE 4
E2SULT-Inhibiting and T4-TTR–Competing Potencies of the 24 PCBs and the Positive Reference Compounds T4 and PCP,
Respectively, in the TTR-Binding and E2SULT Assays
Compound
E2SULT inhibitiona TTR binding
IC50 (lM) ± SD
E2SULT activity
at 10lM compared
with control (%) IC50 (lM) ± SD T4-REP ± SD
T4 binding at 10lM
compared withcontrol (%)
PCB-19 þ 71 — — 126
PCB-28 þ 42 — — 88
PCB-47 þþb 47 — — 103
PCB-51 þþ 38 — — 122
PCB-52 þþ 53 — — 98
PCB-53 þ 45 — — 114
PCB-74 — 98 — — 99
PCB-80 — 94 —c — 60
PCB-95 þþ 59 — — 107
PCB-100 þþþb 44 — — 104
PCB-101 þþþb 63 — — 101
PCB-104 þþb 53 — — 112
PCB-118 þ 78 — — 82
PCB-122 — 113 0.79 ± 0.23d 0.083 ± 0.035 45
PCB-125 þ 82 3.7 ± 0.4 0.014 ± 0.003 6
PCB-126 — 97 > 15 < 0.0038 78
PCB-128 þ 85 — — 83
PCB-136 — 91 — — 84
PCB-138 þe 74 > 15 < 0.0038 66
PCB-153 — 97 > 15 < 0.0038 73
PCB-168 — 90 1.3 ± 0.2 0.041 ± 0.011 10
PCB-170 — 97 > 15 < 0.0038 74
PCB-180 — 93 > 15 < 0.0038 73
PCB-190 — 106 > 15 < 0.0038 77
T4 ND ND 0.057 ± 0.010 1.0 ± 0.0 11
PCP 0.29 ± 0.06 3 ND ND ND
Note. n ¼ 2; —, no response; ND, not determined.
aNo IC50 values could be determined for the E2SULT assay. þ, > 20% inhibition at 10lM; þþ, > 20% inhibition at 3lM; þþþ, > 20% inhibition at 1lM.
bE2SULT-inhibiting compounds with maximum inhibition levels (plateau) of 38–58% of the maximum inhibition by PCP.
cNo IC50 value could be determined because at PCB-80 concentrations > 1lM, the dose-dependent decrease in T4-TTR binding leveled off to a plateau level of
60% of the maximum T4-TTR binding at 10lM (see Fig. 1).
dAlthough 50% inhibition was observed at IC50 ¼ 0.8lM, T4-TTR binding leveled off from this concentration to a plateau level of 45% of the maximum
T4-TTR binding at 10lM.
e> 20% inhibition was found at 0.3–10lM, but not in a dose-dependent way.
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and 136 could not be classified in any of the four clusters and
stood apart from the other congeners, given their moderate ER-
agonistic potencies.
Contribution of Individual NDL-PCB Congeners to the Toxic
Potency in Complex Mixtures
For the congeners tested in the present study, PCB con-
centrations in human samples declined in the order Spain 
Sweden > Japan > China (Table 6). In all five data sets,
PCB congener composition in human samples was dominated
(> 50%) by hexachlorinated PCBs, followed by heptachlori-
nated PCBs in Europe and Japan and by pentachlorinated
PCBs in China (Fig. 3; Supplementary table 1). Wang et al.
(2010b) attributed the relatively low PCB concentrations
and the different congener pattern in Chinese samples, as
compared with European studies, to a shorter time span of
production and usage of PCBs and lower influence of dietary
intake in China.
Due to the relatively small variation in REP values (Tables 2–
5), the contribution of different PCB congeners to the overall
GJIC-inhibiting, AR-antagonistic, and neurotoxic potencies gen-
erally reflected the molar composition pattern of the samples, with
most abundant congeners contributing most to the calculated
potency (Fig. 3). This observation was most obvious for the GJIC-
inhibiting potency. Relatively high REP values caused a higher
contribution to the neurotoxic potencies by PCB-180 in the
European and Japanese studies and by PCB-118 in the Chinese
study. Similarly, a relatively high AR-antagonistic REP value
resulted in a higher antiandrogenic contribution of PCB-118 than
expected based on its analyzed levels, whereas a relative low REP
value resulted in a lower contribution of PCB-153. In addition, the
Chinese study made clear that PCB-168, which had the highest
AR-antagonistic REP value but was not analyzed in the other
studies, is an important contributor to overall AR-antagonistic
potency (Fig. 3). Also for the TTR-binding potency of PCBs in
human samples, the Chinese case study data identified PCB-168
FIG. 1. Typical examples of dose-response curves for NDL-PCBs in the in vitro bioassays: antagonistic responses toward the AR (A) and ER (B), inhibition
of E2SULT (C), agonistic responses toward the ER (D), competition with T4 for TTR binding (E), and inhibition of GJIC (F). For each mechanism of action,
results are presented for one or more exemplary NDL-PCBs and the positive reference compound used to calculate REP values. Values on the x-axis represent
molar concentrations.
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as an important congener, contributing to > 80% of the calculated
T4-competing potency. Estrogenic potencies could be attributed
by 76–100% to PCB-28, whereas antiestrogenic potencies mostly
reflected the composition of predominant higher chlorinated PCBs
138, 153, 170, 180, and 190.
DISCUSSION
Epidemiological studies have found associations between
exposure to PCBs and effects on reproduction and (neuro)-
development, thyroid system, nervous system, immune system,
cardiovascular system, growth, lipid metabolism, diabetes, and
obesity (e.g., reviews by ATSDR, 2000; EFSA, 2005; Hatch
et al., 2010; Korrick and Sagiv, 2009; Meeker and Hauser,
2010; Wang et al., 2010a). Many of the observed associations
are still under scientific study and debate because they lack
mechanistic support, are not expected at the measured exposure
levels, or could not be confirmed in other studies.
In general, observed associations between PCB exposure and
human effects are difficult to be attributed to either DL- or NDL-
PCBs because humans are simultaneously exposed to both classes
of PCBs. By comparing results from animal studies with single
DL- or NDL-PCB congeners, however, Rice (2004) concluded
that, except for PCB-126, ‘‘there is not much difference in potency
between the DL and NDL congeners’’ on reproductive/
developmental, thyroid, immune, and neuropsychological func-
tions, which are ‘‘presumably the most sensitive functional
endpoints’’ to PCB exposure. This comparison, however, is
hampered by the limited number of congeners that have been
studied to date and the possible DL contamination of the NDL-
PCB standards used in these animal studies.
Results from the present study with ultrapure PCB congeners,
however, indicate that individual NDL-PCB congeners may
exert specific mechanisms of action in vitro that may be well
associated with some of the effects observed in epidemiological
and animal studies. Interference with sex steroid signaling (AR-
and ER-CALUX and E2SULT inhibition bioassays) may be
linked to the observed association in humans between PCB
exposure and effects on reproductive health in males (semen
quality and sperm DNA integrity) and females (menstrual
irregularities, miscarriage, fetal death, and decreased gestational
age) and on sex ratio of newborns (e.g., ATSDR, 2000; Brouwer
et al., 1999; EFSA, 2005; Meeker and Hauser, 2010). Thyroid
hormone disruption (TTR-binding assay and UGT gene
expression) may be linked to hypothyroidism, which in turn
affects neurodevelopmental outcomes such as psychomotor
development, mental development, IQ, memory, and hearing
(Brouwer et al., 1999; Trnovec et al., 2008). Decreased GJIC may
be closely linked to the carcinogenic potency of PCBs, which has
unequivocally been demonstrated in animal studies (ATSDR,
2000) but is still an issue of debate for the human situation. A recent
weight of evidence evaluation (Golden and Kimbrough, 2009) did
not support a causal relationship between PCB exposure and
human cancer, although the U.S. Environmental Protection
Agency and the International Agency for Research on Cancer
have classified PCBs as ‘‘probably carcinogenic to humans.’’
In Vitro Toxicity of NDL-PCBs in Relation to Their Structure
All PCBs in the test set had AR-antagonistic potencies
similar to or higher than flutamide, an antiandrogenic drug used
in prostate cancer treatment. Structural requirements for AR-
antagonistic potency of PCBs were not obvious, but highest
potencies were found for PCB-168 and PCB-125, with di-ortho
chlorine substitution in one phenyl ring and non-ortho sub-
stitution in the other ring. PCB-190 also meets this description,
but its AR-antagonistic potency was not higher than observed
for other congeners. Relative AR-antagonistic potencies of PCB-
138 > PCB-153 > PCB-180 observed in DHT-exposed AR-
CALUX cells confirmed results in R1881-exposed CHO cells
transiently transfected with an AR-responsive luciferase reporter
gene (Bonefeld-Jørgensen et al., 2001). In the present study, DL-
PCBs and NDL-PCBs had similar AR-antagonistic potencies,
suggesting that ortho substitution in PCBs is a less critical
requirement for antiandrogenic potencies than in PBDEs (Harju
et al., 2007). Similar to PBDEs, none of the tested PCB
congeners exhibited AR-activating potencies, possibly because
TABLE 5
Inhibition of GJIC by the 24 PCBs and REP toward the Most
Potent Congener PCB-136 in the Scrape-Loading Dye Transfer
Assay with WB-F344 Cells
Compound
IC50 (lM)
± SD PCB-136 REP
% Control
GJIC at 10lM
PCB-19 6 ± 0.8 0.7 11
PCB-28 15 ± 2.4 0.3 73
PCB-47 13 ± 1.0 0.4 55
PCB-51 7 ± 0.7 0.6 21
PCB-52 9 ± 2.2 0.5 44
PCB-53 6 ± 0.6 0.8 7
PCB-74 18 ± 1.3 0.3 82
PCB-80 — — 100
PCB-95 8 ± 2.0 0.6 24
PCB-100 16 ± 1.8 0.3 77
PCB-101 13 ± 3.4 0.4 60
PCB-104 8 ± 1.2 0.6 26
PCB-118 19 ± 0.5 0.2 72
PCB-122 22 ± 4.2 0.2 82
PCB-125 13 ± 1.0 0.4 66
PCB-126 — — 96
PCB-128 13 ± 0.7 0.3 60
PCB-136 5 ± 0.9 1.0 0
PCB-138 14 ± 1.0 0.3 68
PCB-153 16 ± 2.3 0.3 73
PCB-168 23 ± 6.7 0.2 83
PCB-170 30 ± 2.9 0.2 92
PCB-180 43 ± 10.3 0.1 87
PCB-190 23 ± 4.7 0.2 85
Note. n ¼ 3; —, no response.
94 HAMERS ET AL.
 at V
rije Universiteit- Library on June 4, 2013
http://toxsci.oxfordjournals.org/
D
ow
nloaded from
 
PCBs have no hydrogen-bonding ability, unlike the natural
ligands testosterone and DHT (Harju et al., 2007).
Weak ER-agonistic potency was observed for lower
chlorinated PCBs with 2,2#,6- or 2,4,4# substitution and
combinations thereof. Further substitution in meta positions 3
or 5 clearly diminished or abolished ER-agonistic potencies,
except for tetra-ortho-chlorinated PCB-136, which was,
together with the other tetra-ortho-chlorinated PCB-104, the
most potent ER agonist among the tested PCBs. Potent ER
binding by tetra-ortho-chlorinated PCBs has been described
before (Matthews and Zacharewski, 2000). Possibly, the
rotational rigidity of this molecule reflects the planar rigidity
of E2 and favors fit of the molecule into the ER pocket
(DeCastro et al., 2006). In general, the observed structure-
activity relationships for ER-agonism confirm earlier studies
with PCBs and structurally related PBDEs in the ER-CALUX
(Hamers et al., 2006; Meerts et al., 2001; Pliskova et al., 2005)
and with PCBs in an MCF-7 proliferation test (Andersson
et al., 1999), with highest estrogenic potency for lower
halogenated compounds preferably with a substitution pattern
in two to four ortho positions and one para position. The
observed ER-antagonistic potency for higher chlorinated PCBs
also confirmed earlier results in the ER-CALUX bioassay, the
MCF-7 proliferation assay, and in transiently transfected
reporter gene assays with MCF-7 and MDA-MB-231 cells
(Bonefeld-Jørgensen et al., 2001; Pliskova et al., 2005).
Except for mono-ortho-chlorinated PCB-28, all other mono-
ortho (PCBs 74, 118, and 122) and non-ortho (PCB-126)
congeners did not show any estrogenic or antiestrogenic
activity in the ER-CALUX bioassay. In contrast, Krishnan and
FIG. 2. HCA of the classified in vitro toxicity profiles of 24 PCBs. Classes (1–5) indicate no toxic potency (1) to very high toxic potency (5) for the different
mechanisms of action according to the criteria given in the Materials and Mehtods section, with an exception for the TTR-binding potency of PCB-80 (see Results section).
TABLE 6
PCB Concentrations (nmol/g Lipid) of the 19 PCB Congeners that Were Tested in the Present Study and
Analyzed in Human Samples, together with Their Overall Calculated Toxic Potencies Expressed in Equivalent
Concentrations (nmol/g lipid) of the Reference Compounds
Tarragona, Spain O¨rebro, Sweden Japan
Anhui Province,
China
Jiangsu Province,
China
Reference Wingfors et al. (2000) Wingfors et al. (2000) Hirai et al. (2005) Wang et al. (2010b) Wang et al. (2010b)
RPCB 2.70 2.51 0.250 0.0492 0.0332
RAR-antagonistic potency (Flu-Eq) 5.75 5.44 0.520 0.301 0.205
RER-agonistic potency (E2-EQ) 0.126 0.105 0.0392 0.0177 0.0186
RER-antagonistic potency (ICI-182,780-EQ) 4.04 3.67 0.308 0.0360 0.0243
RTTR-binding potency (T4-EQ) 0.00905 0.00846 0.000726 0.000459 0.000309
RGJIC-inhibiting potency (PCB-136-EQ) 0.631 0.615 0.063 0.0127 0.0081
RNeurotoxic potency (PCB-53-EQ) 0.494 0.416 0.046 0.00707 0.00457
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Safe (1993) reported that antiestrogenic potencies of coplanar
PCBs in MCF-7 cells correlated with their AhR-activating
potencies. A possible explanation for AhR-mediated inhibition
of E2-induced transactivation is that the activated AhR binds to
inhibitory dioxin-responsive elements (iDREs) present in
promoter regions of E2-responsive target genes (Safe et al.,
1998). The lack of iDREs in the reporter construct of the
ER-CALUX bioassay may explain why antiestrogenic potency
of DL-PCBs was not observed in the ER-CALUX bioassay
(Table 3; Pliskova et al., 2005).
Inhibition of E2SULT activity is an alternative mechanism
by which compounds can exert estrogenic properties. By
inhibiting the formation of inactive E2 sulfonates, indirect
estrogenic effects may appear due to the enhanced bio-
availability of E2 in target tissues. Weak E2SULT-inhibiting
potencies were observed for many PCBs at the highest test
concentration of 10lM. Dose-dependent E2SULT inhibition
could only be determined for four NDL-PCBs, but curve fits
were considered unreliable and not all PCBs inhibited E2SULT
activity in a dose-dependent way. Tetra- or pentachlorinated
PCBs, with a 2,2,#4- or 2,2,#5-substitution pattern, had the
highest E2SULT-inhibiting potencies.
Not only parent NDL-PCB compounds but also their
metabolites may exert (anti)estrogenic activity. In vitro ER-
(ant)agonistic potencies of hydroxylated or methyl-sulfonyl PCB
metabolites have been reported at similar micromolar effect
concentrations as found for their parent compounds (e.g.,
Andersson et al., 1999; Letcher et al., 2002). Moreover,
E2SULT-inhibiting potencies of hydroxylated PCB metabolites
were up to four orders of magnitude higher than observed for
their parent compounds, i.e., IC50 concentrations in the below
nanomolar range (Kester et al., 2000). In conclusion, (anti)-
estrogenic activities of PCB metabolites should be taken into
account in NDL-PCB hazard characterization.
TTR-binding potencies of PCBs were very low or absent.
Up to 10lM test concentrations, full dose-response curves
FIG. 3. Contribution of the individual congeners to the molar composition of the PCB mixture and its calculated toxic potencies in human samples. RPCB and
total toxic potencies are given for each study in Table 6. Not all congeners were analyzed in each study (see Supplementary table 1).
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were only obtained for PCBs 80, 122, 125, and 168. Full
inhibition of T4-TTR binding was only observed for PCBs 125
and 168. The TTR-binding congeners contained a non–ortho-
substituted phenyl ring with chlorine substitution in 3,5 or
3,4,5 positions. In addition, TTR-binding potencies were further
increased when the other phenyl ring was substituted in one
(PCB-122) or two (PCB-125 and PCB-168) ortho positions,
giving the congener a structure resembling reversed triiodothy-
ronine or T4, respectively.
Chauhan et al. (2000) also tested the TTR-binding potency
of 47 different PCB congeners, but surprisingly poor cor-
respondence was observed for the 16 congeners that were also
tested in the present study. Similar to the present study,
Chauhan et al. (2000) found highest TTR-binding potency for
PCB-80 (IC50 ¼ 7nM), but no IC50 value could be estimated in
the present study because TTR binding leveled off to
a maximum of 40% T4-TTR–binding inhibition (Fig. 1). For
the remaining 15 PCB congeners, even bigger differences were
found between both studies. At 10lM test concentrations, we
found very weak TTR binding for PCBs 138, 153, and 180 and
no TTR binding at all for PCBs 95, 100, and 101, whereas
Chauhan et al. (2000) reported IC50 values for these congeners
ranging from 28 to 690nM. No explanations are available for
the discrepancies between both studies, especially when taking
into account that sensitivities toward the natural ligand T4 were
highly comparable, i.e., IC50 values of 57 (Table 4) versus
49nM (Chauhan et al., 2000).
Similar to E2SULT inhibition, hydroxylated PCB metabo-
lites have TTR-binding potencies in the same order of
magnitude as the natural ligand T4, whereas their parent
compounds have very low or no binding potency at all
(Lans et al., 1993). To determine the effect of PCB exposure on
T4-TTR binding, information is required about biotrans-
formation rates of PCBs, as well as the identity, fate, and
TTR-binding potency of their hydroxylated metabolites.
Alternative to TTR binding, PCBs can act as thyroid
hormone disruptors by inducing T4 glucuronidation causing
increased hepatic clearance of T4 (Hood and Klaassen, 2000).
Therefore, the effect of PCBs was tested on mRNA expression
of T4-glucuronidating isozymes UGT1A1 and UGT1A6
(Vansell and Klaassen, 2002). Upregulation of UGT1A6 ex-
pression by DL-PCBs, as observed in the rat hepatoma H4IIE
cell line, is most likely caused by AhR activation. Upregulation
of UGT1A6 by NDL-PCBs is in vivo most likely caused by
activation of the constitutive androstane receptor (CAR)
(Shelby and Klaassen, 2006). It is not clear, however, if the
observed in vitro upregulation of UGT1A6 by PCB-138 in
H4IIE cells is also CAR mediated because the H4IIE cell line
hardly expresses CAR (Fery et al., 2010).
The GJIC-inhibiting potencies of highly purified PCB
congeners corresponded with the previous data obtained with
37 PCB standards that were not purity checked (Machala et al.,
2003). In both studies, noncoplanar congeners had highest
GJIC-inhibiting potencies, but the observation that 2,2#,
6-substituted congeners had higher potencies than 2,2#- or
2,6-substituted congeners was more pronounced in the present
study. In addition, PCBs 52, 95, and 136 were > two times
more potent than previously reported. Also Hemming et al.
(1991) have suggested that GJIC inhibition increases with the
number of chlorinated ortho positions. These results suggest
that the PCB-induced acute closure of GJIC is a result of
a specific mechanism and is not due to unspecific membrane
perturbations. PCBs can induce long-term disruption of GJIC
via increased internalization and degradation of connexin43
and via inhibition of connexin43 transport, as was recently
demonstrated for PCB-153 in rat liver epithelial cells
(Simeckova et al., 2009).
Toxicity Profiling
Multivariate statistical methods pointed out that the PCB test
set could be divided into at least four different clusters. Such
classification can be used to identify common structural
features that are typical for a given toxicity profile. As
expected, DL-PCB congeners 74, 118, and 126 were classified
together in a single cluster (cluster III) based on their ability to
induce AhR-mediated UGT1A6 expression. Two additional
mono-ortho-chlorinated congeners in the test set, i.e., PCBs 28
and 80, displayed no UGT1A6 induction and were classified in
different clusters. PCB-80 was classified in cluster II together
with congeners sharing a non-ortho 3,4,5-chlorination pattern
on one ring and 1 or 2 chlorinated ortho positions on the other
ring. Classification in cluster II was clearly driven by the TTR-
binding activity, which is not surprising given the overlap
in substitution pattern between these PCB congeners and T4.
Other hexa- to heptachlorinated PCBs with di-ortho sub-
stitution in 2,6 or 2,2# positions were classified in a separate
cluster I, mainly based on their weak ER-antagonistic potency.
PCB-28 was classified in cluster IV together with congeners
characterized by a 2,5-substitution pattern (subcluster IV.1) or
a 2,6- or 2,(3,)4-substitution pattern (subcluster IV.2) in one of
the phenyl rings. The tetra-ortho-chlorinated PCBs 104 and
136 both had deviating toxicity profiles due to their moderate
ER-agonistic potencies, which were not observed for any of the
other PCBs. The toxicity profile of PCB-136 did not fit into any
of the four clusters distinguished in the test set, whereas the
profile of PCB-104 was in-between cluster IV (2,6 substitution
in one ring) and PCB-136.
Toxic Potency of PCBs in Human Samples and Contribution
of the Individual Congeners
Based on the IC50 levels, AR antagonism was apparently the
most sensitive endpoint affected by the tested NDL-PCB. The
calculated total potency in human samples ranged from 0.2 to
6 nmol Flu-Eq/g lipid (Table 6). In flutamide treatment of
prostate cancer, the main metabolite 2-hydroxy-flutamide has
an average therapeutic steady-state concentration of 940 ng/ml
in plasma (Schulz et al., 1988), which can be calculated into
IN VITRO TOXICITY PROFILING OF NDL-PCB CONGENERS 97
 at V
rije Universiteit- Library on June 4, 2013
http://toxsci.oxfordjournals.org/
D
ow
nloaded from
 
6 lmol Flu-Eq/g lipid, based on a sevenfold higher affinity of
the metabolite for the human AR than flutamide (Simard et al.,
1986), a molecular weight of flutamide of 276.2 g/mol, and
a plasma lipid content of 4 g/l. These data suggest that the
calculated AR-antagonistic potency of complex PCB mixtures
in humans is 1000–30,000 times lower than the therapeutic
potency, which can effectively compete with natural andro-
genic hormones for binding to prostate AR in humans. It
should be realized, however, that this margin of safety was
calculated for ‘‘average’’ and not for highly exposed human
populations and that 2-hydroxy-flutamide is cleared from the
body much faster (half-life < 1 day) than the persistent PCBs.
This holds especially for the most abundant NDL-PCBs 138,
153, 170, 180, and 168, which also contributed most to the AR-
antagonistic potency in human samples (Fig. 3).
The observation that most abundant NDL-PCBs contribute
most to the calculated total toxic potency in the human samples
does not hold only for the individual congeners but of course also
for different classes of congeners, based on ortho-substitution
level, chlorination level, status as indicator PCB (yes or no), or
toxicity profiles (Supplementary figs. 2–5). For instance, the
dominance of di-ortho-substituted PCBs (> 69%) and hexa- and
heptachlorinated biphenyls (> 63%) in the molar composition of
the human samples was reflected by a> 68 and> 51% dominance,
respectively, of these groups in the calculated toxic potencies.
Two exceptions were observed, i.e., (1) the ER-agonistic potency
is 100% dominated by tri- to pentachlorinated PCBs, of which
76–100% by PCB-28, and (2) the neurotoxic potency in the
Chinese study is dominated for> 58% by mono-ortho-substituted
tri- to pentachlorinated PCBs 28, 74, and 118. The most potent
AhR-activating DL-PCB-126 contributed at maximum 0.2%
to any of the calculated toxic potencies, i.e., the AR-antagonistic
potency in the Japanese study.
The complex PCB mixtures in human samples consisted
for 71–86% of indicator PCBs including PCB-118 and for
55–81% excluding PCB-118. Except for the AR-antagonistic
and TTR-binding potencies in the Chinese case study, the set of
indicator PCBs including PCB-118 could explain 74–100% of
the calculated toxic potencies in the human samples and
48–100% excluding PCB-118. From the Chinese case study, it
became clear that PCB-168, which was not analyzed in the
European and Japanese studies, is the most important ‘‘non-
indicator’’ congener. On average, a 0.96 ratio was found
between molar concentrations of PCB-168 and the most
abundant congener PCB-153. Making up 18–19% of the molar
composition of the PCB mixture, PCB-168 explained 60–61%
of the AR-antagonistic, 81–82% of the TTR-binding, and 14%
of the GJIC-inhibiting potencies calculated for the Chinese
study. Assuming a similar PCB-168:PCB-153 ratio for the
European and Japanese case study, it was estimated that PCB
concentrations would increase on average by 30% (Europe) and
7% (Japan) if PCB-168 was taken into account. Consequently,
estimated AR-antagonistic potencies would increase by a factor
3.8 for the European and a factor 1.7 for the Japanese case study,
TTR-binding potencies by a factor 4.7 and 2.0, and GJIC-
inhibiting potencies by a factor 1.2 and 1.1, respectively.
Representative PCBs from all four distinguished toxicity
profiles were only analyzed in the Chinese study. In general,
almost half of the RPCB levels consisted of cluster I congener
PCBs 138, 153, 170, and 180, whereas the other half was
equally divided by clusters II, III, and IV. As could be expected
from the toxicity profiles, all four clusters contributed to GJIC
and AR-antagonistic potencies, albeit that the latter was
dominated by cluster II (PCB-168) rather than by cluster I.
ER-agonistic potency was completely attributed to cluster IV
(PCB-28) and ER-antagonistic potency to cluster I. Cluster II
(PCB-168) dominated the TTR-binding potency, whereas it did
not contribute to the neurotoxic potency.
CONCLUSIONS
The present study demonstrates that ultrapure NDL-PCBs
have in vitro toxic potencies, which are not mediated through
AhR activation but may well be associated with reprotoxic,
neurotoxic, and carcinogenic effects observed in animal studies
and epidemiological studies. Four different in vitro toxicity
profiles could be distinguished for the set of 24 tested PCBs, of
which one could be attributed to AhR activation by DL-PCBs
and three others to combinations of non–AhR-mediated
mechanisms of action. Due to the small variation in REP
values, most abundant congeners also contributed most to the
calculated toxic potencies of complex PCB mixtures analyzed
in human samples. PCB-168 was recognized as a congener that
is not regularly monitored but may contribute considerably to
the AR-antagonistic and TTR-binding potency of the complex
mixture of PCBs in human samples. Therefore, it is rec-
ommended to extend the set of seven indicator PCBs with
PCB-168 for future human monitoring studies. Based on the
current knowledge of PCB levels in human tissues and toxic
potencies of individual congeners, the seven indicator PCBs
plus PCB-168 may explain on average > 74% of the calculated
toxic potency of PCB mixtures in humans. The studied
bioassays reflect critical mechanisms of action that may well
underlie toxicities observed in in vivo and in epidemiological
studies. Current risk assessment procedures for PCBs only
consider the AhR-activating DL-PCBs. According to the
results of the present study, however, DL-PCBs only have
a minor contribution to the non–AhR-mediated toxic potencies
calculated for complex PCB mixtures found in the general
human population. Therefore, NDL-PCBs should be included
in future risk assessment concepts.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.
oxfordjournals.org/.
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